These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1125 related items for PubMed ID: 23769318

  • 1. Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.
    Li YY, Lam SK, Mak JC, Zheng CY, Ho JC.
    Lung Cancer; 2013 Sep; 81(3):354-361. PubMed ID: 23769318
    [Abstract] [Full Text] [Related]

  • 2. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
    Wang CY, Chao TT, Chang FY, Chen YL, Tsai YT, Lin HI, Huang YC, Shiau CW, Yu CJ, Chen KF.
    Lung Cancer; 2014 Aug; 85(2):152-60. PubMed ID: 24954871
    [Abstract] [Full Text] [Related]

  • 3. Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.
    Wang M, Zhao J, Zhang LM, Li H, Yu JP, Ren XB, Wang CL.
    J Cancer Res Clin Oncol; 2012 Dec; 138(12):2069-77. PubMed ID: 22821179
    [Abstract] [Full Text] [Related]

  • 4. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G, Kronenberger P, Teugels E, Umelo IA, De Grève J.
    BMC Med; 2012 Mar 21; 10():28. PubMed ID: 22436374
    [Abstract] [Full Text] [Related]

  • 5. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
    Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, Tenen DG, Kobayashi S.
    PLoS Med; 2007 Oct 21; 4(10):1669-79; discussion 1680. PubMed ID: 17973572
    [Abstract] [Full Text] [Related]

  • 6. [Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].
    Han R, Wang X, Zhong D, Zhao J, Chen Z, Sun L, Wang J, Zhang J.
    Zhongguo Fei Ai Za Zhi; 2012 Dec 21; 15(12):689-93. PubMed ID: 23249714
    [Abstract] [Full Text] [Related]

  • 7. YM155 sensitizes non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitors through the mechanism of autophagy induction.
    Dai CH, Shu Y, Chen P, Wu JN, Zhu LH, Yuan RX, Long WG, Zhu YM, Li J.
    Biochim Biophys Acta Mol Basis Dis; 2018 Dec 21; 1864(12):3786-3798. PubMed ID: 30315932
    [Abstract] [Full Text] [Related]

  • 8. Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation.
    Qu G, Liu C, Sun B, Zhou C, Zhang Z, Wang P.
    Oncol Rep; 2014 Jul 21; 32(1):341-7. PubMed ID: 24842595
    [Abstract] [Full Text] [Related]

  • 9. The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib.
    Zou Y, Ling YH, Sironi J, Schwartz EL, Perez-Soler R, Piperdi B.
    J Thorac Oncol; 2013 Jun 21; 8(6):693-702. PubMed ID: 23575415
    [Abstract] [Full Text] [Related]

  • 10. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells.
    Han W, Pan H, Chen Y, Sun J, Wang Y, Li J, Ge W, Feng L, Lin X, Wang X, Wang X, Jin H.
    PLoS One; 2011 Jun 21; 6(6):e18691. PubMed ID: 21655094
    [Abstract] [Full Text] [Related]

  • 11. Inducible EGFR T790M-mediated gefitinib resistance in non-small cell lung cancer cells does not modulate sensitivity to PI103 provoked autophagy.
    Moreira-Leite FF, Harrison LR, Mironov A, Roberts RA, Dive C.
    J Thorac Oncol; 2010 Jun 21; 5(6):765-77. PubMed ID: 20421816
    [Abstract] [Full Text] [Related]

  • 12. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
    Zou M, Xia S, Zhuang L, Han N, Chu Q, Chao T, Peng P, Chen Y, Gui Q, Yu S.
    Int J Oncol; 2013 Jun 21; 42(6):2094-102. PubMed ID: 23588221
    [Abstract] [Full Text] [Related]

  • 13. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
    Cha MY, Lee KO, Kim M, Song JY, Lee KH, Park J, Chae YJ, Kim YH, Suh KH, Lee GS, Park SB, Kim MS.
    Int J Cancer; 2012 May 15; 130(10):2445-54. PubMed ID: 21732342
    [Abstract] [Full Text] [Related]

  • 14. Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.
    Soucheray M, Capelletti M, Pulido I, Kuang Y, Paweletz CP, Becker JH, Kikuchi E, Xu C, Patel TB, Al-Shahrour F, Carretero J, Wong KK, Jänne PA, Shapiro GI, Shimamura T.
    Cancer Res; 2015 Oct 15; 75(20):4372-83. PubMed ID: 26282169
    [Abstract] [Full Text] [Related]

  • 15. Luteolin is effective in the non-small cell lung cancer model with L858R/T790M EGF receptor mutation and erlotinib resistance.
    Hong Z, Cao X, Li N, Zhang Y, Lan L, Zhou Y, Pan X, Shen L, Yin Z, Luo L.
    Br J Pharmacol; 2014 Jun 15; 171(11):2842-53. PubMed ID: 24471765
    [Abstract] [Full Text] [Related]

  • 16. Regulation of epidermal growth factor receptor tyrosine kinase inhibitor resistance via Ambra1-mediated autophagy in non-small cell lung cancer.
    Chen YH, Yang Y, Xu LJ, Deng Y, Fu JW.
    J Physiol Pharmacol; 2023 Jun 15; 74(3):. PubMed ID: 37661184
    [Abstract] [Full Text] [Related]

  • 17. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
    Park KS, Raffeld M, Moon YW, Xi L, Bianco C, Pham T, Lee LC, Mitsudomi T, Yatabe Y, Okamoto I, Subramaniam D, Mok T, Rosell R, Luo J, Salomon DS, Wang Y, Giaccone G.
    J Clin Invest; 2014 Jul 15; 124(7):3003-15. PubMed ID: 24911146
    [Abstract] [Full Text] [Related]

  • 18. Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells.
    Choi JM, Jang JY, Choi YR, Kim HR, Cho BC, Lee HW.
    Lung Cancer; 2015 Nov 15; 90(2):175-81. PubMed ID: 26342551
    [Abstract] [Full Text] [Related]

  • 19. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
    Lv T, Li Z, Xu L, Zhang Y, Chen H, Gao Y.
    Acta Biomater; 2018 Aug 15; 76():257-274. PubMed ID: 29960010
    [Abstract] [Full Text] [Related]

  • 20. Resistance to EGFR-TKI can be mediated through multiple signaling pathways converging upon cap-dependent translation in EGFR-wild type NSCLC.
    Patel MR, Jay-Dixon J, Sadiq AA, Jacobson BA, Kratzke RA.
    J Thorac Oncol; 2013 Sep 15; 8(9):1142-7. PubMed ID: 23883783
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.